I-Mab

I-Mab operates as a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel or differentiated biologics to treat diseases with unmet medical needs, particularly cancers and autoimmune disorders. The company was founded by Jingwu Zang on June 30, 2016 and is headquartered in Pudong, China.

I-Mab operates as a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel or differentiated biologics to treat diseases with unmet medical needs, particularly cancers and autoimmune disorders. The company was founded by Jingwu Zang on June 30, 2016 and is headquartered in Rockville, MD.

Allakos Inc

Horizon Pharma

ImmunityBio

Mind Medicine MindMed

SAGE Therapeutics

SpringWorks Therapeutics Inc

As the market gets back to normal, it's a great time to explore the pharma stocks that got lost in the vaccine frenzy of the past year. The post 7 of the Best Pharma Stocks to Buy Now appeared first on InvestorPlace.

7 of the Best Pharma Stocks to Buy Now

Blueprint Medicines

Johnson & Johnson

Legend Biotech

ContextLogic Inc

Mirum Pharmaceuticals Inc

CANbridge will make a $10 million upfront payment for the two Fabry and Pompe candidates. Guangzhou Link Health Pharma and Australia's George Clinical plan to form a China clinical CRO JV that will conduct trials for Link Health's in-licensed portfolio.

Week In Review: CANbridge Licenses LogicBio's Adeno-Associated Virus For Gene Therapies In $591 Million Deal

SHANGHAI and GAITHERSBURG, Md., April 29, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in May.

I-Mab Announces Upcoming Participation at May Conferences

SHANGHAI and GAITHERSBURG, Md., April 28, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the Company has filed its annual report on Form 20-F for the full year ended December 31, 2020 with the U.S. Securities and Exchange Commission ("SEC") on April 28, 2021.

I-Mab Filed 2020 Annual Report on Form 20-F

I-Mab (NASDAQ: IMAB) has announced topline results from its Phase 2 study evaluating olamkicept (also known as TJ301) in patients with active ulcerative colitis (UC). The study met its primary endpoint and provided early evidence that I-Mab's IL-6 inhibitor improves outcomes, including rectal bleeding.

I-Mab's IL-6 Drug Hits Primary Endpoint Goal In Mid-Stage Ulcerative Colitis Study

SHANGHAI and GAITHERSBURG, Md., April 26, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced positive topline results from its regional multi-center, randomized, double-blind and placebo-controlled phase 2 study (NCT03235752) evaluating the efficacy and safety of olamkicept (also known as TJ301) administered intravenously biweekly in patients with active ulcerative colitis (UC).

I-Mab Announces Positive Topline Phase 2 Results for Olamkicept in Ulcerative Colitis

SHANGHAI, China., and GAITHERSBURG, MD, April 14, 2021 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that its abstract on proprietary and highly differentiated CD73 antibody uliledlimab (also known as TJD5, or TJ004309) has been selected for detailed poster presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place virtually June 4-8, 2021.

I-Mab Announces Selected Poster Presentation of CD73 Antibody Uliledlimab at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

SHANGHAI, China and GAITHERSBURG, Md., March 31, 2021 (GLOBE NEWSWIRE) -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologic, today announced its participation in the following conferences in April. Details of the conferences and management presentation are as follows:

I-Mab Announces Upcoming Participation at April Conferences

SHANGHAI, China and GAITHERSBURG, Md., March 30, 2021 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the development of novel biologics, and ABL Bio, Inc. (Kosdaq:298380, hereafter “ABL”), a South Korean biotech specializing in bispecific antibody technology, jointly announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for initiating phase 1 trial for bispecific antibody TJ-CD4B/ABL111. The phase 1 clinical trial will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of TJ-CD4B/ABL111 in advanced or metastatic solid tumors.

I-Mab and ABL Bio Receive US FDA Approval to Initiate Phase 1 Trial of Bispecific Antibody TJ-CD4B/ABL111 in Patients with Advanced or Metastatic Solid Tumors

SHANGHAI, China and GAITHERSBURG, Md., March 29, 2021 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced financial results for the full year ended December 31, 2020 and provided key business updates.

I-Mab Reports Financial Results for Full Year of 2020 and Provides Business Updates

Mandarin session on April 7, 2021 and English session on April 26, 2021 for investors and research analysts

I-Mab to Host 2021 R&D Day

SHANGHAI, China and GAITHERSBURG, Md., March 19, 2021 (GLOBE NEWSWIRE) -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today filed a prospectus supplement with the Securities and Exchange Commission (the “SEC”) to register 19,050,555 ordinary shares, including ordinary shares represented by American depositary shares (“ADSs”) of I-Mab, held by Gaoling Fund, L.P. and YHG Investment, L.P. (collectively “Hillhouse”). Hillhouse acquired these ordinary shares pursuant to a series of subscription agreements dated September 3, 2020 through a private placement (the “PIPE Agreements”). The Company is filing a shelf registration to register the aforementioned ordinary shares, including ordinary shares represented by ADSs, to satisfy contractual registration rights of Hillhouse in the PIPE Agreements. Currently, Hillhouse beneficially owns 22,492,602 ordinary shares of the Company, or 13.3% of the total outstanding ordinary shares.

I-Mab Files Prospectus Supplement for Shelf Registration for Hillhouse

Shares of the U.S.-listed Chinese immuno-oncology company I-Mab (NASDAQ: IMAB) offer strong upside potential, according to a Needham analyst.  The I-Mab Analyst: Chad Messer initiated coverage of I-Mab shares with a Buy rating and $75 price target.

I-Mab Poised To Capitalize On Growing Oncology Sector, Needham Says In Bullish Initiation

I-MAB BioPharma is a new player in the global pharmaceuticals market with autoimmune products.

I-MAB BioPharma And Its Dual Drug Portfolio

- New Initiative is part of I-Mab's long-term strategy to drive innovation and scientific leadership in immuno-oncology - New collaborations signed will allow I-Mab access to cutting edge technology platforms to develop novel drug molecules - I-Mab continues to focus on delivering on key clinical programs while building pipeline of next generation assets

I-Mab Launches Discovery Initiative to Expand Transformational Immuno-Oncology Pipeline

Adagene

Eli Lilly

Morphosys AG - ADR

Adagene completed a $140 million NASDAQ IPO and climbed 56% higher in open market trading. Nuance Pharma in-licensed Greater China rights to a late-stage candidate for osteoarthritis pain from Antibe Therapeutics in a $100 million agreement.

Week In Review: Suzhou's Adagen Raises $140 Million In U.S. IPO To Develop Oncology Drugs

Coherus BioSciences

Dynavax Technologies

Exelixis

Illumina

Week In Review: Junshi Signs $1.1 Billion Deal For U.S.-Canada Rights To PD-1

SHANGHAI and GAITHERSBURG, Md., Feb. 5, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced the commencement of a proposed registered...

Proposed Registered Secondary Public Offering of American Depositary Shares by Certain Pre-IPO Shareholders of I-Mab

SHANGHAI and GAITHERSBURG, Md., Feb. 4, 2021 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first patient has been dosed in a phase...

I-Mab Announces First Patient Dosed in Phase 2 Clinical Trial of TJ107 in Glioblastoma Multiforme in China

SHANGHAI, China and PLANEGG/MUNICH, Germany, Jan. 25, 2021 /PRNewswire/ -- I-Mab (Nasdaq: IMAB), and MorphoSys (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) today announced that the first patient has been dosed in a phase 1 dose escalation study to evaluate the safety,...

I-Mab and MorphoSys Announce First Patient Dosed in U.S. Phase 1 Study of TJ210/MOR210 in Patients with Advanced Cancer

SHANGHAI and GAITHERSBURG, Md., Dec. 1, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today filed a registration statement on Form F-1 with the...

I-Mab Files Shelf Registration Statement for PIPE Investors

SHANGHAI and GAITHERSBURG, Md., Dec. 1, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced the strengthening of its Scientific Advisory...

I-Mab Appoints Leading Immunology and Hematology Experts to Its Scientific Advisory Board

In a GuruFocus article on Nov. 17, I took a look at three of the nine public Chinese biotechnology companies that are projected to become major international competitors in the coming years, according to FiercePharma. In this article, let's take a look at the prospects for numbers four through six on the list.

High-Potential Chinese Biotechs: Hua Medicine, I-MAB and Innovent Biologics

BeiGene

BioNTech SE

Calliditas Therapeutics AB

Merck

Pfizer

Thermo Fisher Scientific

Innoforce, a Hangzhou company, formed a JV with Thermo Fisher Scientific to build a large biologics and steriles drug development and manufacturing facility in the Hangzhou Airport Economic Demonstration Area. Decheng Capital had good reason to be pleased when Merck paid $2.75 billion to acquire VelosBio, a company formed in 2017 to develop ROR1 ADCs for cancer.

Week In Review: RemeGen, A Yantai Biologics Company, Completes $515 Million Hong Kong IPO

SHANGHAI and GAITHERSBURG, Md., Nov. 13, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that it will hold a call with investors on...

News for I-Mab Stock (IMAB)